Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Buy, Sell, or Hold: Questcor Pharmaceuticals

Don't let it get away!

Keep track of the stocks that matter to you.

Help yourself with the Fool's FREE and easy new watchlist service today.

When considering any stock for your portfolio, don't be swayed by just the positives. Examine its pros and cons, and decide whether it's possible upside outweighs its risks. Let's take a look at Questcor Pharmaceuticals (Nasdaq: QCOR  ) today and see why you might want to buy, sell, or hold it.

Founded in 1990 and based  in Anaheim, Calif., Questcor has a market capitalization of about $1.6 billion. It's a biopharmaceutical company targeting  conditions such as multiple sclerosis, nephrotic syndrome, collagen diseases, rheumatic disorders, and infantile spasms. One of its key products is its Acthar Gel, an injectible drug. Over the past year, Questcor shares have dropped 36%, leading some to wonder whether it's a bargain.

One reason to consider buying Questcor is its business. With the world's population growing, getting older, and living longer, demand for health-care products and services is likely to remain in demand.

Another plus is that unlike many biotech companies, Questcor actually has products on the market, generating revenue. Its flagship product, Acthar, is seeing its sales grow very rapidly. And Questcor isn't relying just on that. It's moving into rheumatology now, too.

Lots of numbers in its financial statements look good: Revenue and earnings have been growing at accelerating rates, recently topping 80%. Free cash flow has gone from  a loss of $14 million in 2006 to a positive $40 million in 2009 to $166 million in the past 12 months. Profit margins were very sizable even a few years ago, but they've been getting even stronger, with net margins recently at 39%. Returns on assets, equity, and invested capital: all hefty and growing.

Questcor's brand-new dividend is another attraction, recently yielding a solid 3.1%. There are only a few dozen  dividends of that size or greater among health-care companies. You can certainly do better, such as via PDL BioPharma's (Nasdaq: PDLI  ) hefty 8% yield, but its future is a bit uncertain, as the company's revenue growth has slowed and some valuable patents will be expiring soon.

Then there's valuation. With the stock down so much lately, it looks attractive. Its recent P/E ratio of 10 is about half its five-year average P/E, and its forward P/E of 7 is about half of that of the S&P 500.

Of course, all is not completely rosy for this company. The stock was just about slashed in half on a single day in September, when insurer Aetna (NYSE: AET  ) said it would limit coverage for Acthar. It's true that Aetna represents only about 5% of Acthar sales, but its decision has many wondering whether other insurers will follow suit, which could be disastrous. The company, so far, is maintaining that this decision won't have much of a material effect on its business. It might be right -- UnitedHealth Group (NYSE: UNH  ) , for example, recently tweaked its Acthar policies in only minor ways.

Another worry is a recent investigation into Questcor's marketing practices, accompanied by some lawsuits. Even if the company emerges victorious, these kinds of things can sap its time, energy, and resources -- like cash. My colleague Keith Speights has noted, for example, that just settling can be costly, with Amgen (Nasdaq: AMGN  ) paying a $780 million settlement last year, and Pfizer (NYSE: PFE  ) paying $2.3 billion.

Those factors reflect another: volatility. If you can't stomach sharp swings in a stock's price, perhaps look elsewhere.

The role of Acthar in Questcor's revenue is another worry: If it takes a big hit, so will the company. It's always good to have a more diversified revenue base, to dilute risks. Indeed, news of a new generic competitor recently knocked the stock down some. And other competition exists, too -- it another, better drug for MS comes along, that will be bad for Questcor.

Hold (off)
Given the reasons to buy or sell Questcor, it's not unreasonable to decide to just hold off on it. You might want to wait for the investigation into its marketing practices to be resolved, and for it to be clear whether other insurers will limit Acthar's reimbursement. You might want to see a wider range of products in its stable, too.

The verdict
I'm holding off on Questcor for now, but I'm intrigued as well. Everyone's investment calculations are different, though. Do your own digging and see what you think. Questcor may perform spectacularly in the coming years, but remember that there are plenty of compelling stocks out there.

Questcor is one of the most debated names in all of biotech. Acthar is growing at a torrid pace -- and minting money in the process. But is it worth the risk? See what our analysts think in our brand-new premium research report on Questcor. In it, you'll learn about the key opportunities and threats facing the company, as well as multiple reasons to buy and sell the stock. We're providing a full year of analyst updates as key news hits, so make sure to claim a copy today by clicking here now.

Read/Post Comments (1) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On November 26, 2012, at 3:24 PM, MrKaching wrote:

    Growth is all about growing EPS.

    QCOR has this EPS and will explode upwards over the next 5 years. Possibly get bought out at a very higher price as well.

    Definitely a buy and add on dips if you are an investor. As for traders, well lots of volatility here to the up and downside. Shorts appear to be bailing though.

Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2125496, ~/Articles/ArticleHandler.aspx, 10/28/2016 3:49:19 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,183.03 13.35 0.07%
S&P 500 2,127.79 -5.25 -0.25%
NASD 5,200.18 -15.79 -0.30%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/28/2016 3:33 PM
AET $107.47 Down -3.36 -3.03%
Aetna CAPS Rating: ***
AMGN $144.71 Down -15.86 -9.88%
Amgen CAPS Rating: ****
PDLI $3.28 Down -0.05 -1.50%
PDL BioPharma CAPS Rating: ***
PFE $32.01 Down -0.47 -1.45%
Pfizer CAPS Rating: ****
QCOR.DL $0.00 Down +0.00 +0.00%
Questcor Pharmaceu… CAPS Rating: **
UNH $140.42 Down -1.52 -1.07%
UnitedHealth Group CAPS Rating: ****